Lapatinib

Drug Profile

Lapatinib

Alternative Names: 572016; Cipatinib; GSK-572016; GW-2016; GW-572016; GW-572016F; Lapatinib ditosilate; Lapatinib ditosylate; Tycerb; Tykerb; Tyverb

Latest Information Update: 13 Jun 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer Beth Israel Deaconess Medical Center; Eddingpharm; FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO; GlaxoSmithKline; Novartis
  • Class Antineoplastics; Chlorobenzenes; Fluorobenzenes; Furans; Phenyl ethers; Quinazolines; Small molecules; Sulfones
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III Brain metastases
  • Phase II Colorectal cancer; Non-small cell lung cancer
  • Discontinued Gastric cancer; Head and neck cancer; Prostate cancer

Most Recent Events

  • 02 May 2017 Novartis terminates a phase II trial due to lack of significant signal of efficacy in Brain metastases (Combination therapy) in USA (IV) (NCT01934894)
  • 27 Feb 2017 Lapatinib is still in phase I/II trials for Breast cancer (Combination therapy, First-line therapy, Metastatic disease) in Japan
  • 01 Feb 2017 GlaxoSmithKline terminates a phase II clinical trial in Non-small cell lung cancer (Monotherapy, Late-stage disease, Metastatic disease) due to lack of efficacy in Canada, USA (PO) (NCT00073008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top